In vitro cell models of HR+BC cell lines harboring TP53 mutations introduced by the CRISPR‐Cas9 method might help to clarify whether or not sensitivity to estrogen deprivation is directly dependent on the TP53 status. Here, TP53 is linked to breast cancer.